Mr. Todd Shapiro reports

RHELION LIFE SCIENCES' WHOLLY OWNED SUBSIDIARY FILAMENT HEALTH TO DELIVER ORAL COMMENTS AT FDA PUBLIC HEARING ON THE POTENTIAL FUTURE THERAPEUTIC USE OF PSYCHEDELIC DRUGS

Sarit Hashkes, president of Rhelion Life Sciences Corp.'s wholly owned subsidiary Filament Health Corp., will deliver oral comments at the United States Food and Drug Administration (FDA) public hearing on Considerations for Potential Future Therapeutic Use of Psychedelic Drugs, being held virtually and in person today, Sept. 14, 2026.

The hearing has been convened by FDA's Center for Drug Evaluation and Research to gather input on the development, evaluation and potential future therapeutic use of psychedelic drugs. Filament is among the organizations providing oral remarks during the public comment period.

The full hearing will be streamed live on the FDA's Youtube channel -- again, Mr. Hashkes will be speaking around 3:40 p.m. ET.

More info on the hearing's agenda.

"We plan to seize this important moment while remaining grateful and honoured for the opportunity to speak directly with the FDA," said Todd Shapiro, chief executive officer of Rhelion Life Sciences. "Filament has spent years building deep expertise in pharmaceutical-grade psychedelics across multiple jurisdictions, and we look forward to contributing meaningfully to this important dialogue. Our intention is to ensure Rhelion is ready on day 1 should the United States establish a regulated access pathway. We applaud the FDA for convening this groundbreaking hearing and for its thoughtful, forward-looking approach to how psychedelic medicines can responsibly help Americans in need."

PEX010 is Filament's patented, standardized, GMP manufactured botanical psilocybin drug candidate, produced using proprietary extraction, purification and stabilization methods that give investigators consistent composition across every dose, every study and every research site. On April 30, 2026, the company completed its previously announced acquisition of Filament Health Corp., including its portfolio of 77 issued patents across 13 patent families and its lead drug candidate, PEX010.

Filament supplies PEX010 as an investigational drug product. Participation in the FDA public hearing does not constitute an endorsement of the company, of Filament or of PEX010 by FDA, or by any other regulatory authority. PEX010 has not been approved by FDA or by any other regulatory authority for any indication.

About Rhelion Life Sciences Corp.

Rhelion Life Sciences is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary, Filament Health Corp., the company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with leading institutions around the world.

We seek Safe Harbor.